REP 2139-Ca is the calcium chelate complex formulation of REP 2139.
Zadaxin is thymosin alpha 1
Pegasys is pegylated interferon alpha 2a
Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is > 2000 copies / ml.
After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys.

Hepatitis B, Chronic

REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.

REP 2139-Ca

Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection

Zadaxin

Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.

Pegasys

Farabi General Hospital

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

To record side effects, symptoms and adverse effects of exposure to REP 2139-Ca in monotherapy and when combined with Zadaxin and / or Pegasys.

To assess antiviral activity of REP 2139-Ca in monotherapy and when combined with Zadaxin and / or Pegasus including serum HBsAg, HBeAg, anti-HBsAg antibodies, anti-HBeAg antibodies and HBV DNA.

ribose/lafyèv

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Baz done ki pi konplè remèd fèy medsin te apiye nan syans